Publications and press releases

News Release | 17 January 2012
Urinary Proteome Analysis enables personalized medicine

Diabetes mellitus affects almost 10% of the European population. The number of patients has increased significantly within the last years and the expenditure on patients with diabetes accounts for 15% of the European health care budget expenditure. Most patients suffer from type 2 diabetes. Furthermore, decreasing age at diagnosis and prolonged duration of diabetes contribute to an increased development of diabetic complications. Diabetic nephropathy is one of the major complications. In progress of disease, glomerular filtration rate reduces gradually over a period of months or years. This eventually leads to end-stage renal disease requiring renal replacement therapy i.e. dialysis and/or kidney transplantation.

PRIORITY is a European research project that started on 1 January 2012 aiming at the early identification of patients at risk for subsequent preventive therapy and analysis of its effects.

Dr Peter Rossing from Steno Diabetes Center near Copenhagen is coordinator of PRIORITY. Other participants are mosaiques diagnostics, Glasgow University, University Hospital Zürich and Hannover Clinical Trial Center.

Urinary proteome analysis is an innovative technology approach having demonstrated its high accuracy and reliability in more than 40 clinical trials so far. After identification of patients at risk, the project aims at showing positive effects of treatment with aldosterone blockade on top of standard therapy.

3280 type 2 diabetic patients will be included in this project. About 20% are at-risk patients and will be assigned to aldosterone blocker. Patients who are classified as being at low risk for progression to diabetic nephropathy will continue to receive usual care. “Our objective is to show the significant benefit the specific therapy provides for affected patients”, says Professor Harald Mischak from mosaiques diagnostics.



Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs DM, Mischak H, Mullen W, Navis G, Noutsou M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Snell-Bergeon J, Spasovski G, Stojceva-Taneva O, Trillini M, von der Leyen H, Winklhofer-Roob BM, Zürbig P, Jankowski J.

”Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy”

Nephrol Dial Transpl 2014 Aug;29(8):1563-70. doi: 10.1093/ndt/gfu039.


Currie G, Delles C.

”Proteinuria and its relation to cardiovascular disease”

Int J Nephrol Renovasc Dis. 2013 Dec 21;7:13-24. doi: 10.2147/IJNRD.S40522.


Currie G, McKay G and Delles C.

"Biomarkers in diabetic nephropathy: Present and future"

World J Diabetes 2014 December 15; 5(6): 000-000 (in press).


Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles C, von der Leyen H, Mischak H, Navis G, Noutsou M, Ortiz A, Ruggenenti PL, Rychlik I, Spasovski G, Rossing P.

”Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial”

BMJ Open. 2016 Mar 2;6(3):e010310. doi: 10.1136/bmjopen-2015-010310. PubMed PMID: 26936907; PubMed Central PMCID: PMC4785328.


Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.

”Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides”

J Am Soc Nephrol. 2015 Aug;26(8):1999-2010. doi: 10.1681/ASN.2014050423. Epub 2015 Jan 14. PubMed PMID: 25589610; PubMed Central PMCID: PMC4520165.


Pontillo C, Jacobs L, Staessen JA, Schanstra JP, Rossing P, Heerspink HJ, Siwy J, Mullen W, Vlahou A, Mischak H, Vanholder R, Zürbig P, Jankowski J.

A urinary proteome-based classifier for the early detection of decline in glomerular filtration

Nephrol Dial Transpl, 2016 Jul 6. pii: gfw239. [Epub ahead of print].


Lindhardt M, Persson F, Zürbig P, Stalmach A, Mischak H, de Zeeuw D, Lambers Heerspink H, Klein R, Orchard T, Porta M, Fuller J, Bilous R, Chaturvedi N, Parving HH, Rossing P.

”Urinary Proteomics Predict Onset of Microalbuminuria in Normoalbuminuric Type 2 Diabetic Patients, a sub-study of the DIRECT-Protect 2 Study”

Nephrol Dial Transpl, doi:10.1093/ndt/gfw292:


Small HY, Currie GE, Delles C.

”Prostasin, proteases, and preeclampsia”

J Hypertens. 2016 Feb;34(2):193-5. doi: 10.1097/HJH.0000000000000828. PubMed PMID: 26682786.


Mischak H, Delles C, Vlahou A, Vanholder R.

”Proteomic biomarkers in kidney disease: issues in development and implementation”

Nat Rev Nephrol. 2015 Apr;11(4):221-32. doi: 10.1038/nrneph.2014.247. Epub 2015 Feb 3. Review. PubMed PMID: 25643662.